Edgewise TherapeuticsEWTX
EWTX
About: Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases.
Employees: 108
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
349% more call options, than puts
Call options by funds: $60M | Put options by funds: $13.3M
219% more first-time investments, than exits
New positions opened: 51 | Existing positions closed: 16
47% more capital invested
Capital invested by funds: $1.84B [Q2] → $2.71B (+$870M) [Q3]
33% more funds holding in top 10
Funds holding in top 10: 6 [Q2] → 8 (+2) [Q3]
25% more funds holding
Funds holding: 140 [Q2] → 175 (+35) [Q3]
22% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 46
0.99% less ownership
Funds ownership: 109.1% [Q2] → 108.11% (-0.99%) [Q3]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$45
46%
upside
Avg. target
$49
59%
upside
High target
$51
66%
upside
4 analyst ratings
4 positive
100%
0 neutral
0%
0 negative
0%
Evercore ISI Group Cory Kasimov 21% 1-year accuracy 3 / 14 met price target | 62%upside $50 | Outperform Maintained | 17 Dec 2024 |
Truist Securities Srikripa Devarakonda 33% 1-year accuracy 10 / 30 met price target | 62%upside $50 | Buy Maintained | 27 Nov 2024 |
Wedbush Laura Chico 32% 1-year accuracy 20 / 62 met price target | 46%upside $45 | Outperform Maintained | 8 Nov 2024 |
Piper Sandler Yasmeen Rahimi 48% 1-year accuracy 14 / 29 met price target | 66%upside $51 | Overweight Maintained | 11 Oct 2024 |
Financial journalist opinion
Based on 5 articles about EWTX published over the past 30 days
Neutral
Zacks Investment Research
3 days ago
EWTX Stock Rises on Upbeat Data From Rare Muscular Disorder Study
Data from a mid-stage study show that treatment with Edgewise's experimental drug reduces levels of a biomarker related to skeletal muscle damage.
Positive
Benzinga
4 days ago
Edgewise Therapeutics' Lead Candidate Reduces Biomarker Levels In Mid-Stage Study In Patients With Muscle Weakness Disease
On Monday, Edgewise Therapeutics, Inc., EWTX revealed topline results from the Phase 2 CANYON trial of sevasemten in individuals with Becker muscular dystrophy (BMD), is a genetic disorder that causes progressive muscle weakness.
Neutral
Business Wire
5 days ago
Edgewise Therapeutics Announces Positive Topline Results from the CANYON Phase 2 Trial of Sevasemten in Individuals with Becker Muscular Dystrophy (Becker)
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced positive topline results from the Phase 2 CANYON trial of sevasemten in individuals with Becker muscular dystrophy. Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor designed to protect muscle against contraction-induced damage in muscular dystrophies. The trial met its primary endpoint of change from baseline in CK. C.
Neutral
Business Wire
2 weeks ago
Edgewise Provides Statement Regarding Company's Relationship with Dr. Han Phan at Rare Disease Research
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today provided information regarding the company's relationship with Dr. Han Phan at Rare Disease Research. On November 27, 2024, the U.S. Food and Drug Administration (FDA) issued a warning letter to Dr. Phan based on a 2024 site inspection related to her work with another company. This warning letter is unrelated to any Edgewise clinical trial or data. None of the.
Neutral
Business Wire
3 weeks ago
Edgewise Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024, at 1 pm ET. The presentation will be webcast live; a link for the webcast can be found on the Edgewise Events & Presentations page and will be accessible for replay, for a limited time, following the conference. It is recommended that.
Neutral
Business Wire
1 month ago
Edgewise Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the third quarter of 2024 and recent business highlights. “We continue to make strong progress on our cardiac and skeletal muscle programs,” said Kevin Koch, Ph.D., President and Chief Executive Officer of Edgewise. “Based on the strength of clinical and preclinical data to-date, we are treating patients with obstructive and non-o.
Neutral
Business Wire
2 months ago
Edgewise Therapeutics to Present on Sevasemten (EDG-5506) for Becker Muscular Dystrophy (Becker) at the 29th International Annual Congress of the World Muscle Society
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced its participation at the 29th International Annual Congress of the World Muscle Society (WMS) with an industry-sponsored symposium and the presentation of seven scientific posters. These presentations will highlight the effects of sevasemten in individuals with Becker based on findings from the DUNE and ARCH clinical trials, as well as provide perspec.
Positive
Benzinga
2 months ago
Analysts Think There's Still Time To Get In On Edgewise
Edgewise Therapeutics EWTX is a small-cap pharmaceutical stock that has been all the rage recently. Shares are up 55% in the last three months and up 332% over the past 52 weeks.
Positive
Benzinga
2 months ago
Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge
Edgewise Therapeutics EWTX is up 50% in a single session and 450% from recent lows for a reason. Its novel, oral, selective treatment for obstructive hypertrophic cardiomyopathy did remarkably well in early trials.
Positive
MarketBeat
2 months ago
Analyst Think There's Still Time to Get in on Edgewise, Up 332%
Edgewise Therapeutics NASDAQ: EWTX is a small-cap pharmaceutical stock that has been all the rage recently. Shares are up 55% in the last three months and up 332% over the past 52 weeks.
Charts implemented using Lightweight Charts™